Quantum Biopharma (QNTM) Other Non-Current Liabilities (2018 - 2026)
Quantum Biopharma recorded quarterly Other Non-Current Liabilities of $5.3 million in Q1 2026, down 31.47% quarter-over-quarter from $7.8 million in Q2 2025, and up 87.19% year-over-year from $2.8 million in Q1 2025.
Quantum Biopharma's Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $5.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 87.19% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (up 87.19% YoY), while the FY2024 annual figure was $212002.0, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $5.3 million for Q1 2026 at Quantum Biopharma, down from $7.8 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $7.8 million in Q2 2025 to a low of $1.0 in Q2 2024.
- A 5-year average of $1.4 million and a median of $388481.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities slumped 100.0% in 2024 and surged 776068300.0% in 2025, its largest moves.
- Quantum Biopharma's Other Non-Current Liabilities stood at $243594.0 in 2022, then sank by 46.48% to $130383.0 in 2023, then surged by 62.6% to $212002.0 in 2024, then surged by 3560.67% to $7.8 million in 2025, then slumped by 31.47% to $5.3 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $5.3 million, $7.8 million, and $2.8 million for Q1 2026, Q2 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.32 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2025 | 2.84 Mn |
| Dec 31, 2024 | 212,002.00 |
| Sep 30, 2024 | 75.00 |
| Jun 30, 2024 | 1.00 |
| Sep 30, 2023 | 130,383.00 |
| Jun 30, 2023 | 122,351.00 |
| Mar 31, 2023 | 450,544.00 |
| Dec 31, 2022 | 243,594.00 |
| Sep 30, 2022 | 388,481.00 |
| Jun 30, 2022 | 425,620.00 |
| Mar 31, 2022 | 522,884.00 |
| Dec 31, 2021 | 5.14 Mn |
| Sep 30, 2021 | 1.43 Mn |
| Jun 30, 2021 | 1.71 Mn |
| Mar 31, 2021 | 2.00 Mn |
| Dec 31, 2020 | 4.97 Mn |
| Sep 30, 2020 | 2.61 Mn |
| Dec 31, 2019 | 4.35 Mn |
| Dec 31, 2018 | 3.37 Mn |